The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
about
Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry dataAll-in-one processing of heterogeneous human cell grafts for gene and cell therapy.Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Minimal residual disease in acute myeloid leukaemiaImpact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML.Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignanciesClinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemiaDevelopment of Flow Cytometry-Fluorescent In Situ Hybridization (Flow-FISH) Method for Detection of PML/RARa Chromosomal Translocation in Acute Promyelocytic Leukemia Cell LineMicrofluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from blood.A reliable Raman-spectroscopy-based approach for diagnosis, classification and follow-up of B-cell acute lymphoblastic leukemiaPersistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantationImmunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia?Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia.Immunophenotyping by Multiparameter Flow Cytometry.High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.Minimal residual disease detection using flow cytometry: Applications in acute leukemia.Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.Acute Myeloid Leukemia: How Do We Measure Success?Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.Clinical analysis and optimization of postremission therapy for acute myeloid leukemia patients with minimal residual disease as determined by flow cytometryDefining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter settingLymphocyte subsets: reference ranges in an age- and gender-balanced population of Omani healthy adults.Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission.CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34+ Acute Myeloid Leukemia.Guidelines on the use of multicolour flow cytometry in the diagnosis of haematological neoplasms. British Committee for Standards in Haematology.Immunophenotype-defined sub-populations are common at diagnosis in childhood B-cell precursor acute lymphoblastic leukemia.
P2860
Q24605194-8DBB1AAE-585D-4520-B86F-22C0057B4CD4Q30387995-AC226083-F521-4171-A7E4-6507BBEBE4FAQ33832709-72B13FDB-35DE-40CD-9452-65364551ABC0Q34179265-A9DC26C7-AD32-4FA2-A464-FB9D547F808AQ34877613-0AFB8223-6D3B-4BAE-B3E1-2AA8628D2B9AQ34924495-01AC1E3A-D228-4CF2-A9B7-4DD3722E4CEDQ35554703-AE3157C9-5BAC-427B-9174-0AC5F5C5CE07Q35604619-BEE610CA-0556-46F0-9D44-F37B782E2EC0Q36369838-339C7F17-AB34-482B-ACB2-2CE398A93A2DQ36430867-B4CAB191-EFFE-43C3-B43C-A76D45BC7CE6Q36810101-55880956-2496-4047-AF1E-A984051F58DBQ36920398-8CDE8488-6967-47DC-98EF-F282C1B76222Q37133515-B37FB1E9-774D-40B1-8567-AB04E9EE5F28Q37954583-7362B6B3-A81A-49CC-B253-C308309F39E8Q38096909-F584738E-D763-4550-AF51-1E7FA95EE8C3Q38212956-6C78877D-86BC-4F60-9518-6F926C15F3A9Q38240563-1786B9F8-EE0E-4511-8DA9-F7A1BC3D2A20Q38245928-C0B6D9C1-8358-437F-8EAF-E6F29264BCAFQ38666234-E2AD3AEE-4DB2-45FE-9A32-8CB6B4653872Q38809840-B41CCA3A-5743-4C4C-A52B-E86BE2193CA4Q38852472-003D87F9-FF49-4C67-B318-A21498299B62Q38881996-76904547-5C32-45B4-A0F6-5B59ACDB409CQ38948650-5B84D883-DC6A-4861-8C68-1AF3278D7156Q39285841-07BE4723-2AD1-450C-BD24-5ECF0BDB9495Q39474999-80C067EB-5EED-42A0-8A15-E36FC7A53B8CQ41973082-34079A47-5BF5-43AA-BA12-21EF93ED4FB3Q42108788-AB46152D-678E-4A60-B776-F54B931E0602Q42585493-1BB9EAD1-0BDA-4E4B-B7CF-0B2A44F25B88Q43530027-B0FA9CE0-5262-4673-AF2D-128022A05B31Q43555651-32030147-8056-4AF9-9078-EB9E85BC1B32Q44222759-5927311D-CE7E-42A3-80E4-559E848F2522Q47734674-27D50C69-6ABE-4FE4-8387-B3A98AD3C902Q48272424-DE62897C-3848-4A41-8978-C275A2D4286FQ48621761-3C785B95-2B9C-487E-99A4-0F475811D129Q53110546-338EA353-5675-4FE7-8DD1-372D2881EB82Q53600589-698F1DE9-41AF-4239-AA69-0862717C0966Q54364307-C77EF4AA-12C6-44DA-A347-2EB589CF3EE8
P2860
The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The role of multiparameter flo ...... ase in acute myeloid leukemia.
@en
The role of multiparameter flo ...... ase in acute myeloid leukemia.
@nl
type
label
The role of multiparameter flo ...... ase in acute myeloid leukemia.
@en
The role of multiparameter flo ...... ase in acute myeloid leukemia.
@nl
prefLabel
The role of multiparameter flo ...... ase in acute myeloid leukemia.
@en
The role of multiparameter flo ...... ase in acute myeloid leukemia.
@nl
P356
P1476
The role of multiparameter flo ...... ease in acute myeloid leukemia
@en
P2093
David Gillis
P356
10.1309/AJCP5TSD3DZXFLCX
P407
P577
2009-01-01T00:00:00Z